Japan-based Nipro has signed an agreement to acquire US-based medical device firm Infraredx, allowing the firm to expand its intravascular imaging solutions.


Terms of the deal have not been disclosed.

Established in 1999, Infraredx is involved in designing and marketing technologies to treat patients with coronary artery disease.

The deal will allow Nipro to enhance its expertise in near infrared spectroscopy (NIRS) and intravascular ultrasound, in addition to introducing its cardiovascular product line in the US.

Nipro president Yoshihiko Sano: "Nipro and Infraredx share a strong patient centered focus and the combination of the companies’ global portfolio and cardiovascular expertise will help us deliver the most comprehensive imaging solution available to change how cardiovascular disease is managed."

Infraredx produces TVC Imaging System that is used to diagnose and treat coronary artery disease.

In March this year, Infraredx introduced new Advanced TVC Imaging System and the Muller NIRS-IVUS Catheter at the American College of Cardiology’s 2015 Annual Scientific Meeting in San Diego.

The firm developed FDA-cleared Advanced TVC Imaging System to identify lipid-core plaques (LCPs), which will complicate stenting procedures and suspected to cause most heart attacks.

Infrared president and CEO Jason Bottiglieri said: "By teaming up with one of the leading global medical equipment manufacturing companies in the world, Infraredx is able to leverage Nipro’s global network and vast resources to enhance its presence and impact a larger audience locally as well globally."

Subject to certain conditions, the deal is expected to be completed by the end of October this year.

Nipro provides products and technologies for a wide range of fields, including artificial organs, circulatory devices, test/diagnostic agents, injection/infusion solutions, ethical pharmaceuticals, and medical glass products.

Image: Nipro to acquire US-based medical device firm Infraredx. Photo: courtesy of adamr/ FreeDigitalPhotos.net.